Donate For Public and Patients Store Search

F113 - Translating Evidence into Practice: Acne Guidelines

Monday, March 4; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Utilize antibiotics, hormonal therapies and isotretinoin appropriately in acne patients.
  • Formulate effective treatment plans for patients with acne.
  • Evaluate the current evidence of the role of diet in the care of the patients with acne.


The most recent AAD Guidelines of Care for Acne Management were published in 2016 and will be reviewed in this session. The session will include how such guidelines are developed and emphasize treatment pearls for the clinician. Controversies regarding isotretinoin, systemic antibiotics, and hormonal therapies will be discussed. Diet and it's role in acne will also be reviewed. The goal of these presentations will be to provide information which allow practitioners to better manage acne patients. MOC credit will be available for those attendees who answer audience response questions. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at


  • Bowe, Whitney, MD: AQUIS – C(Fees); Body Kitchen, LLC – Independent Contractor(Fees); Boots – Independent Contractor(Fees); Dermalogica – C(Fees); EOS – C(Fees); Ferndale Laboratories, Inc. – C(Fees); Galderma Laboratories, L.P. – A(H), C(H); Genuine Health, USA – C(H); Glowbiotics – C(H); Haus Bioceuticals, Inc – C(Fees); uBiome – A(SO);
  • Harper, Julie Claire, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – SP(H); Aqua – C(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Sun Pharmaceutical Industries Ltd. – C(Fees); Taro Pharm – A(H); Valeant Pharmaceuticals North America LLC – SP(H);
  • Keri, Jonette Elizabeth, MD, PhD: Dermira – A(H); Hoffman-La Roche Ltd. – C(Fees); Ortho Dermatologics – A(H); Pierre Fabre Dermatologie – A(H); Sonoma Pharmaceuticals – A(NC); Sun Pharmaceutical Industries Ltd. – A(H);
  • Kirby, Joslyn S., MD: AbbVie – SP(H); ChemoCentryx – C(Fees); Incyte Corporation – C(H);
  • Pathy, Arun L., MD: no financial relationships exist with commercial interests.
  • Weiss, Jonathan S., MD: AbbVie – I(Grants/Research Funding), SP(H); Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding); Almirall – SP(H); Celgene Corporation – I(Grants/Research Funding); Endo International plc – I(Grants/Research Funding); Foamix – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Moberg Pharma North America LLC – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Ortho Dermatologics – SP(H); Promius Pharma, LLC – I(Grants/Research Funding); Regeneron – SP(H); Sanofi Genzyme – SP(H); UCB – A(H); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
Monday, March 4
9:00 AM
Dr. Keri / Introduction
9:05 AM
Dr. Pathy / Guideline Development and Important Clinical Pearls from the Guidelines
9:25 AM
Dr. Weiss / Isotretinoin in the Treatment of Acne
9:45 AM
Dr. Harper / Hormonal Therapies for Acne
10:05 AM
Dr. Kirby / Antibiotics in the Treatment of Acne
10:25 AM
Dr. Bowe / Diet and Acne
10:45 AM
All faculty / Questions from Session
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 146A
  • CME Credits
  • Type
  • Jonette Elizabeth Keri, MD, PhD, FAAD
  • Arun L. Pathy, MD, FAAD
  • Jonathan S. Weiss, MD, FAAD - Handout
  • Joslyn S. Kirby, MD, FAAD
  • Julie Claire Harper, MD, FAAD - Handout
  • Whitney Bowe, MD, FAAD